Biotechnology (24) | Management Agreements (24)

Browse by Company

Recent Contracts

Revenue Interest Financing Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and entities managed by HealthCare Royalty Management, LLC (Spero Therapeutics, Inc., Filed With SEC on September 30, 2021)
Cooperation Agreement, dated as of April 16, 2021, by and among uniQure N.V., ForUniqure B.V., Forbion 1 Management B.V., Forbion International Management B.V., and Forbion... (uniQure N.V., Filed With SEC on May 10, 2021)
Amendment dated February 23, 2021 to the Expense Advancement Agreement, dated December 1, 2017 and amended on June 29, 2020, October 26, 2020 and November 30, 2020, by and between... (Leisure Acquisition Corp., Filed With SEC on February 25, 2021)
Management Services Agreement, effective as of October 1, 2014, by and between the Registrant and Araxes Pharma LLC (Kura Oncology, Inc., Filed With SEC on February 24, 2021)
Agreement, by and among ZIOPHARM Oncology, Inc., WaterMill Asset Management Corp. Robert W. Postma, Jamie Vieser, and Holger Weis, dated February 4, 2021 (ZIOPHARM ONCOLOGY INC, Filed With SEC on February 5, 2021)
Second Omnibus Amendment and Agreement dated January 12, 2021 by and between NTN Buzztime, Inc., eGames.com Holdings LLC and Fertilemind Management, LLC (NTN BUZZTIME INC, Filed With SEC on January 15, 2021)
Cooperation Agreement, dated December 10, 2020, by and among Alkermes plc, Elliott Investment Management L.P., Elliott Associates, L.P., Elliott Advisors (UK) Limited and Elliott... (Alkermes plc., Filed With SEC on December 10, 2020)
Amendment dated November 30, 2020 to the Expense Advancement Agreement, dated December 1, 2017 and amended on June 29, 2020 and October 26, 2020, by and between the Company and... (Leisure Acquisition Corp., Filed With SEC on November 30, 2020)
Omnibus Amendment and Agreement dated November 19, 2020 by and between NTN Buzztime, Inc., eGames.com Holdings LLC and Fertilemind Management, LLC (NTN BUZZTIME INC, Filed With SEC on November 23, 2020)
Fee Letter Agreement dated November 12, 2020 by and among the Company, the Avista Funds and the Management Company (Organogenesis Holdings Inc., Filed With SEC on November 18, 2020)